Intercept Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, ICPT, Intercept Pharmaceuticals Inc, priceseries

Intercept Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
13.45
Close
13.81
High
13.98
Low
13.09
Previous Close
13.37
Daily Price Gain
0.44
YTD High
18.17
YTD High Date
Jan 20, 2022
YTD Low
12.50
YTD Low Date
Mar 2, 2022
YTD Price Change
-3.24
YTD Gain
-19.00%
52 Week High
25.27
52 Week High Date
Mar 26, 2021
52 Week Low
11.60
52 Week Low Date
Aug 20, 2021
52 Week Price Change
-7.70
52 Week Gain
-35.80%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 19. 2018
57.72
Jan 31. 2018
62.71
8 Trading Days
8.65%
Link
LONG
Apr 3. 2018
62.83
Apr 19. 2018
69.57
12 Trading Days
10.73%
Link
LONG
Jun 29. 2018
83.91
Jul 16. 2018
93.41
10 Trading Days
11.32%
Link
LONG
Oct 31. 2018
96.01
Nov 12. 2018
103.99
8 Trading Days
8.31%
Link
LONG
Jan 4. 2019
102.35
Jan 29. 2019
113.52
16 Trading Days
10.92%
Link
LONG
Mar 11. 2019
104.85
Mar 22. 2019
110.85
9 Trading Days
5.72%
Link
LONG
Sep 9. 2019
64.46
Sep 23. 2019
68.61
10 Trading Days
6.44%
Link
LONG
Nov 6. 2019
79.17
Dec 6. 2019
108.31
21 Trading Days
36.80%
Link
LONG
Apr 6. 2020
62.85
May 1. 2020
78.80
18 Trading Days
25.38%
Link
LONG
Jan 4. 2021
27.39
Jan 12. 2021
29.61
6 Trading Days
8.12%
Link
LONG
Jan 22. 2021
29.46
Feb 5. 2021
34.99
10 Trading Days
18.77%
Link
LONG
Jun 1. 2021
17.16
Jun 17. 2021
20.24
12 Trading Days
17.95%
Link
LONG
Nov 1. 2021
17.22
Nov 15. 2021
18.11
10 Trading Days
5.18%
Link
Company Information
Stock Symbol
ICPT
Exchange
NasdaqGS
Company URL
http://www.interceptpharma.com
Company Phone
646-747-1000
CEO
Mark E. Pruzanski
Headquarters
New York
Business Address
450 W. 15TH STREET, SUITE 505, NEW YORK, NY 10011
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001270073
About

Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading